Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Fluconazole 150 mg Capsules in Healthy Chinese Subjects
NCT03621072Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2019
- Primary completion
- Jul 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluconazole in candidiasis (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to 72 Hours and Maximum Plasma Concentration at 72 hours. Started Jun 2019; status: completed.
02
Drugs
fluconazole
03
Conditions
candidiasis
Beyond the preview
Go deeper on NCT03621072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621072.